Twist Bioscience: AI-Driven Therapeutics Surge Powers 13th Straight Quarter of Growth, EBITDA Breakeven in Sight
Q2 Fiscal 2026 Earnings Call — May 4, 2026
Twist Bioscience reported second-quarter fiscal 2026 revenue of $110.7 million, up 19.3% year-over-year, extending what is now a 13-consecutive-quarter streak of sequential revenue growth. The headline number was strong, but the real story sits inside the therapeutics segment, which grew 55% year-over-year to $40.8 million — an acceleration from Q1 — driven by broadening adoption of AI-enabled drug discovery workflows. Management raised full-year guidance and maintained its commitment to adjusted EBITDA breakeven in Q4 fiscal 2026, though a modest gross margin miss and a $17.1 million securities class action settlement were among the less flattering elements of the quarter.
Therapeutics Acceleration Is No Longer a One-Client Story
The 55% year-over-year surge in therapeutics revenue is the most significant data point in the quarter, and CEO Emily Leproust was direct about what is driving it. "In 2025, there was excitement definitely on our side, but that excitement came from a very few number of accounts. And now that we are many quarters into this, now it's dozens of accounts that are driving that growth." This is a material shift in the quality of the AI-enabled drug discovery revenue — repeatability across a broad base of customers is categorically different from a handful of large one-time orders, and investors should weigh that accordingly.
Leproust also drew attention to the absolute scale of therapeutics revenue. "A lot of companies in the drug discovery field, they tap out at $50 million a year. And now we are way past that. We're almost there every quarter." At $40.8 million in a single quarter, Twist is running at an annualized therapeutics revenue rate that exceeds what many pure-play drug discovery service providers generate in a full year.
The mechanics of the AI flywheel are worth understanding. As pharma and biotech customers deploy AI models to design antibody candidates, the number of sequences they need to screen expands dramatically. Leproust explained: "If they looked at 100 sequences before, now with AI, they can get thousands. And so it just increases the overall value of the deals. And a lot of companies don't have the capacity to analyze that number of antibodies. And so it enables us to upsell to data and cell characterization." The result is that AI discovery programs pull customers further down Twist's menu — from DNA synthesis into protein expression and functional characterization — meaningfully increasing revenue per engagement.
CFO Adam Laponis added useful color on sizing the AI contribution: "If you look at the outsized growth versus the average of the business, that delta is predominantly AI discovery work." He acknowledged, however, that the company does not always have precise visibility into whether a given order is for model training or active lead generation, a limitation worth noting as analysts attempt to model this segment in isolation.
The AWS Partnership Signals Strategic Validation
Amazon Web Services publicly named Twist as a wet lab partner for Amazon Bio Discovery, AWS's AI-powered drug discovery application, with launch partners including Memorial Sloan Kettering Cancer Center and the GrayLab at Johns Hopkins University. This is not a commercial revenue announcement for Q2 — the partnership was already generating activity in the quarter ahead of the public launch — but its signal value is high. It positions Twist as infrastructure-layer enablement for one of the most well-resourced AI drug discovery platforms being assembled, and it validates the company's end-to-end capability from pooled DNA library synthesis through protein characterization.
Management used the Memorial Sloan Kettering example to illustrate how large-scale AI discovery programs work in practice: an order of approximately 100,000 specific DNA sequences as a pooled library, screened to identify promising candidates, then advanced into individual synthesis, protein expression, and characterization through iterative cycles. The economic logic for Twist is clear — pooled synthesis at scale drives down cost per sequence, making broad exploration feasible, while the iterative follow-on work generates recurring, higher-margin revenue from the same program.
New Complex DNA Capability Could Widen the Addressable Order Pool
President and COO Patrick Finn announced that Twist will soon expand its acceptance rate for DNA sequences to approximately 99.5% of clonal genes and 99.9% of all DNA products broadly, up from current rates of roughly 97% and 99% respectively. The improvement matters commercially because of a dynamic Finn described plainly: "When a single sequence in a larger set does not meet acceptance criteria, customers may choose to route the full set elsewhere." In other words, a marginal rejection rate has historically cost Twist entire orders, not just individual sequences. Closing that gap incrementally captures order share that was previously ceded to competitors.
Finn was clear that delivery of these expanded capabilities will be phased. "We're looking at early access, start with a classic Twist, make a few customers happy and learn as we go, and you'll continue to see the capability ramp up as we go through the quarters." The ramp is not immediate, but the directional commitment is definitive and addresses a real commercial friction point, particularly relevant to customers in nucleic acid therapeutics and plant engineering where sequence complexity requirements are higher.
Finn also offered a notable technology update on acceptance rate improvement over time, providing a clean before-and-after comparison: three years ago, Twist accepted approximately 96% of clonal genes and could manufacture about 97.5% of them. Today, acceptance sits at 97% with a manufacturing success rate of approximately 98.5%. The incremental gains are modest in percentage terms but meaningful at the transaction level given the order-routing dynamic described above.
NGS Reaccelerates, MRD Emerges as a Growth Driver
NGS Applications revenue grew 12% year-over-year and 9% sequentially to $57.4 million, a reacceleration that management flagged as the primary driver of H2 sequential growth. The Q4 target of 20% year-over-year NGS growth is ambitious given the segment has been running below that level, but management cited growing commercial diagnostic adoption, particularly in molecular residual disease testing, as the key catalyst.
The MRD opportunity is technically demanding and strategically important. Leproust described these assays as "pushing the limit of sensitivity, often requiring detection of variants at extremely low allele frequencies," which creates a premium on customized panel design, novel enzymes, and rapid panel turnaround. Critically, MRD panels are consumable-driven workflows that scale with test volume — structurally recurring revenue as clinical adoption broadens. Twist's positioning here, combining high-throughput synthesis with precision probe design, is directly aligned to the requirements of this application.
Within NGS, oncology diagnostics drove the sequential acceleration, with top-10 NGS customers accounting for approximately 39% of NGS revenue. The customer base served 627 NGS applications customers in the quarter, 174 of whom had adopted library preparation products.
Gross Margin Modestly Disappoints; OpEx Reduction Underway
Gross margin expanded 200 basis points year-over-year to 51.6%, but moderated sequentially. Laponis attributed the sequential softness to deliberate investment in IgG characterization capacity and digital infrastructure to support accelerating demand, specifically the 55% therapeutics growth. Management maintained its full-year gross margin guidance of 52% or better and reiterated an expected incremental drop-through of 75% to 80% on additional revenue as automation workflows mature. The sequential softness is explainable but worth watching — if therapeutics continues to grow faster than the automation curve, margin expansion could remain lumpy.
On the operating expense side, Twist reduced 36 positions in April as part of a resource reallocation to higher-return opportunities. Combined with additional cost initiatives, management expects these actions to contribute to a $6 million sequential OpEx improvement in Q4 of fiscal 2026 — a meaningful step toward the EBITDA breakeven target. Operating expenses excluding cost of revenues and litigation costs were $95.8 million in Q2, up from $87.6 million in the prior year, reflecting deliberate investment in the commercial organization and digital infrastructure.
Securities Class Action Settled; Cash Position Narrows
Twist reached an agreement in principle to settle a securities class action for approximately $17.1 million. The company booked $7.2 million in Q2 for litigation settlement costs net of insurance recoveries. While management characterized this as a clean resolution that allows focus to return to operations, the settlement is a real cash outflow and a reminder of the disclosure challenges the company faced in prior periods. Cash, cash equivalents, and short-term investments ended Q2 at $171.7 million, down from $197.9 million at December 31, 2025. The sequential decline reflects $17.6 million in operating cash usage, $7.9 million in CapEx, and a $5 million cash outlay for the Invenra bispecific license and equity investment. With the Q4 EBITDA breakeven target approaching, cash burn should narrow, but the runway warrants monitoring.
Guidance Raised; Full-Year Framework Points to Sustained Momentum
Full-year fiscal 2026 revenue guidance was raised to $442 million to $447 million, implying approximately 17% to 19% growth. Importantly, Laponis confirmed that the raise was more than double the Q2 beat — a structure he described as the raise being driven by DSPS strength in H2, with sequential NGS gains layered on top. For Q3, guidance of $114 million to $115 million implies approximately 19% year-over-year growth at the midpoint. Management noted no expectation of DSPS declining sequentially, with upside optionality tied to new customer acquisition pace in that segment.
The academic and government segment, at $12.8 million in Q2 (up only 3% year-over-year), remains a drag reflecting broader NIH and academic funding pressures. Leproust acknowledged the market is "basically shrinking right now" but framed sequential improvement as evidence of share gains — a defensible but inherently modest growth vector in the current environment. Industry and applied revenue of $5.8 million declined year-over-year from $7 million, a segment that received little management commentary and merits further scrutiny.
Geographic diversification is improving. APAC grew 30% year-over-year to $9.1 million, with China representing only approximately 1% of total revenue — a deliberately de-risked posture that provides meaningful insulation from trade and regulatory disruption. EMEA grew 22% year-over-year, outpacing the Americas at 17%.
Twist Bioscience Corporation Deep Dive
The Silicon-Powered DNA Synthesis Engine
Twist Bioscience operates a highly differentiated business model predicated on industrializing biology through its proprietary silicon-based DNA synthesis platform. Rather than relying on legacy 96-well plastic plates, which are constrained by significant chemical reagent volumes and limited throughput, the company synthesizes thousands of custom oligonucleotides on a single proprietary silicon chip. This semiconductor-inspired approach drastically reduces the microscopic volumes of reagents required and exponentially increases production scale, fundamentally altering the unit economics of DNA manufacturing. By treating biological synthesis as a miniaturized engineering problem rather than a traditional chemistry experiment, the company has positioned itself as the foundational foundry for the modern bio-economy.
The company monetizes this core technology by selling highly precise, physical DNA molecules to researchers and commercial partners across a diversified product portfolio. The core revenue engine is split primarily between Synthetic Biology applications and Next-Generation Sequencing tools. The Synthetic Biology segment encompasses custom clonal genes, gene fragments, and oligonucleotide pools, which are mission-critical raw materials for drug development, agricultural biotechnology, and industrial chemical engineering. The Next-Generation Sequencing segment consists of highly customized target enrichment panels that allow diagnostic companies to isolate specific genetic mutations from blood samples, a process vital for modern precision oncology and liquid biopsies. Furthermore, the company has integrated vertically into Biopharma Solutions, leveraging its massive DNA libraries to offer end-to-end antibody discovery and optimization services. This strategic shift transitions the company from a mere raw material supplier to a high-value strategic partner in therapeutic development, generating upfront service fees and potential downstream milestone payments.
Customer Architecture and the Competitive Landscape
Twist Bioscience serves a sprawling and structurally diverse client base of over 3,500 active accounts, acting as the critical supply layer for the global life sciences sector. The customer architecture spans academic laboratories reliant on government grants, cutting-edge diagnostic providers, and nearly all of the top fifty global pharmaceutical corporations. In recent quarters, a significant acceleration in demand has originated from pharmaceutical and biotechnology customers utilizing artificial intelligence for drug discovery. As these entities deploy machine learning algorithms to design novel therapeutic proteins in-silico, they require massive, high-throughput volumes of physical DNA from Twist to test those computationally generated hypotheses in real-world wet labs.
The company operates within a maturing and intensely contested competitive landscape, facing formidable legacy conglomerates alongside specialized synthetic biology providers. Integrated DNA Technologies, a subsidiary of Danaher Corporation, represents the most entrenched incumbent, leveraging a massive global distribution network, deep penetration into academic laboratories, and recently launched rapid-turnaround gene services. GenScript Biotech is another primary competitor, utilizing low-cost manufacturing infrastructure in Asia to exert aggressive pricing pressure and bundle broad biological services. Other major participants include large life science tools conglomerates like Thermo Fisher Scientific and Agilent. Despite this intense competitive pressure, Twist has carved out a dominant structural position. Industry data from early 2026 suggests Twist commands an estimated 14 percent share of the global synthetic DNA synthesis total addressable market. The company exercises even greater concentration power within its Next-Generation Sequencing segment, where its top ten diagnostic customers account for roughly 36 percent of segment revenues. Geographically, North America dominates the revenue mix, generating over half of total sales, which underscores both regional strength and the strategic imperative to deepen commercial penetration across European and Asia-Pacific markets.
The Wilsonville Moat: Scale and Speed as Competitive Advantages
Twist Bioscience has constructed a formidable economic moat built upon the dual pillars of silicon miniaturization and unparalleled operational scale. The core technological advantage is the silicon chip itself, which miniaturizes the phosphoramidite chemistry of DNA synthesis. This allows the company to drive the marginal cost per base pair structurally lower than legacy competitors while maintaining the extreme sequence accuracy required by clinical-grade applications. Because the platform uses radically fewer toxic chemical inputs per oligonucleotide, the company enjoys a naturally protected cost structure that insulates it from raw material supply chain shocks better than traditional plate-based manufacturers.
This structural cost advantage has been aggressively amplified by the operational maturation of the company manufacturing hub in Wilsonville, Oregon. By centralizing operations and tripling its production capacity in this facility, Twist has compressed manufacturing timelines to a degree that legacy competitors struggle to replicate efficiently. The commercial manifestation of this operational leverage is the Express Genes service, which guarantees a consistent five-day turnaround for synthetic DNA constructs. This unprecedented speed allows the company to capture premium pricing and separate itself from the commoditized tiers of the base-pair market. This pricing power and structural leverage are clearly reflected in the clinical financial metrics of the enterprise, with gross margins systematically expanding from the low 40 percent range in 2024 to an excess of 52 percent in early 2026. This margin profile validates the analytical premise that the company possesses genuine, technology-driven pricing power rather than relying merely on marketing scale.
Industry Dynamics: The AI-Driven Demand Surge and Structural Risks
The structural dynamics of the synthetic biology industry are currently defined by secular tailwinds heavily influenced by the integration of artificial intelligence into the life sciences. As computational models drastically reduce the time required to design novel molecular structures, the bottleneck in drug discovery shifts from computational generation to physical validation. This dynamic creates a highly synergistic opportunity for Twist. AI-enabled discovery translates directly into accelerated, high-volume demand for synthetic DNA, as every computationally generated variant must be physically printed and tested. Additionally, the broader synthetic biology total addressable market is scaling rapidly, transitioning from early-stage academic research into late-stage clinical diagnostics, agricultural sustainability solutions, and advanced industrial bio-manufacturing.
However, these expansive opportunities are counterbalanced by tangible, structural industry risks. The company remains highly sensitive to fluctuations in the macroeconomic funding environment. Academic and early-stage biotechnology customers are heavily reliant on venture capital liquidity and the budgetary cycles of institutions like the National Institutes of Health. Any protracted contraction in healthcare funding or risk capital deployment directly impacts top-line revenue visibility. Furthermore, the company operates a highly automated, capital-intensive manufacturing footprint that requires consistent, high-volume throughput to efficiently absorb fixed overhead costs. Any sustained slowdown in end-market demand could quickly reverse the operational leverage the company has spent years cultivating, placing pressure on its path to absolute profitability.
Growth Catalysts: Next-Generation Products and Data Storage
Beyond its core DNA synthesis engine, Twist is aggressively directing capital toward adjacent technological vectors that serve as future growth drivers. The company is leaning heavily into the clinical diagnostic end markets with its Next-Generation Sequencing target enrichment panels. As the standard of care in oncology shifts toward precision medicine and non-invasive liquid biopsies, diagnostic companies are increasingly relying on customized Twist probes to isolate microscopic genetic mutations from patient blood samples. Because diagnostic companies must undergo rigorous regulatory approvals utilizing specific tools, once a Twist panel is designed into a commercialized clinical assay, it creates a highly recurring, exceptionally sticky revenue stream that is largely insulated from routine price competition.
Another profound, albeit longer-horizon, growth catalyst is the development of DNA data storage technology. As global enterprise and consumer digital data generation vastly outpaces the physical constraints of traditional silicon and magnetic storage infrastructure, Twist is engineering systems to encode binary digital data into the chemical base pairs of synthetic DNA molecules. DNA offers unparalleled data density and extreme physical durability over centuries, requiring zero energy for long-term archival storage. While still navigating pilot phases and early commercial partnerships, successful deployment of enterprise-level DNA data storage archives would exponentially expand the total addressable market of the company far beyond life sciences and into global enterprise data infrastructure, structurally altering the terminal value of the enterprise.
The Enzymatic Frontier: Disruptive Entrants
While Twist utilizes highly optimized traditional chemistry miniaturized on silicon, a new cohort of well-capitalized, disruptive entrants is advancing an entirely different technological paradigm known as enzymatic DNA synthesis. Emerging start-ups and specialized players like DNA Script and Elegen are engineering proprietary biological enzymes to build DNA sequences without the toxic, harsh chemical reagents inherent in the traditional phosphoramidite process. This biological approach allows for clean, benchtop synthesis, theoretically enabling individual laboratories to print their own DNA in-house rather than ordering it over the cloud from a centralized foundry like Twist.
Enzymatic DNA synthesis represents the most credible existential threat to the centralized manufacturing model of the bio-economy. If these new entrants can successfully resolve their existing technical limitations and scale the length, accuracy, and unit economics of their enzymatic reactions, they could effectively decentralize the synthetic biology supply chain. However, analytical scrutiny of the landscape in early 2026 reveals that these enzymatic systems still struggle meaningfully to match the immense high-throughput scale, stringent accuracy, and low cost-per-base efficiency of the Twist silicon platform. The threat is technologically valid and warrants rigorous monitoring, but it remains heavily constrained by the physics and raw economics of scaling biological reactions against deeply entrenched, highly optimized semiconductor manufacturing processes.
Management Execution: From Speculation to Operational Discipline
The strategic evolution of Twist Bioscience over the past several years has been entirely defined by a ruthless transition from a highly speculative, cash-burning growth story into a structurally disciplined, margin-driven enterprise. Under the continuous leadership of the founding management team, the company has successfully navigated the severe deflation of the broader synthetic biology bubble that fundamentally impaired or destroyed many of its less rigorous peers. The executive suite has established a commendable track record of commercial execution, consistently delivering over a dozen consecutive quarters of sequential top-line growth through heavily volatile macroeconomic cycles.
Crucially, management intentionally pivoted the corporate strategy to prioritize manufacturing efficiencies, margin expansion, and operational discipline over purely reckless top-line expansion. The migration and consolidation of production volume into the Oregon facility was executed seamlessly, avoiding the customer fulfillment disruptions that typically plague hardware and manufacturing transitions in the life science tools sector. This operational discipline is further evidenced by a stringent focus on capital allocation and a clearly communicated, credible trajectory toward reaching Adjusted EBITDA breakeven by the end of fiscal 2026. By consistently under-promising and over-delivering on gross margin targets, the executive team has fostered deep credibility with institutional investors who demand execution reliability just as much as technological vision.
The Scorecard
Twist Bioscience has successfully industrialized the foundational layer of modern biotechnology, transforming custom DNA synthesis from a bespoke, labor-intensive laboratory procedure into a highly scalable, high-margin manufacturing engine. The proprietary silicon-based technology affords the company a distinct structural cost and throughput advantage that legacy competitors utilizing traditional methodologies cannot efficiently replicate. This physical moat has been fortified by the seamless operational execution of the centralized manufacturing facility, which enables premium service tiers like Express Genes to capture massive margin leverage. While the emergence of decentralized enzymatic DNA synthesis presents a valid long-term technological threat, the overwhelming centralized scale, absolute clinical accuracy, and aggressive pricing power of the Twist platform dominate the immediate commercial reality. The deep integration of the company into the rigid supply chains of global pharmaceutical giants and high-growth clinical diagnostic firms ensures that its core revenue streams remain exceptionally resilient.
Ultimately, the enterprise is positioned at the critical intersection of biological engineering and artificial intelligence. As machine learning models exponentially increase the velocity of in-silico drug discovery, the volumetric demand for physical DNA to empirically validate those models will scale proportionately. Management has proven its precise ability to capture this accelerating demand while aggressively managing input costs and steering the enterprise toward operational profitability. By expanding decisively into the highly recurring diagnostic target enrichment market and incubating massive long-term optionality in enterprise DNA data storage, the company has secured multiple distinct avenues for sustained commercial expansion. Within the broader bio-economy, the company operates as the premier structural supplier, possessing both the visionary technology to capture emerging downstream markets and the operational discipline to extract tangible, compounding economic value from them.